KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Receivables - Net: 2015-2024

Historic Receivables - Net for CRISPR Therapeutics AG (CRSP) over the last 9 years, with Dec 2024 value amounting to $25.0 million.

  • CRISPR Therapeutics AG's Receivables - Net fell 87.50% to $25.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $25.0 million, marking a year-over-year decrease of 87.50%. This contributed to the annual value of $25.0 million for FY2024, which is 87.50% down from last year.
  • As of FY2024, CRISPR Therapeutics AG's Receivables - Net stood at $25.0 million, which was down 87.50% from $200.0 million recorded in FY2023.
  • CRISPR Therapeutics AG's Receivables - Net's 5-year high stood at $200.0 million during FY2023, with a 5-year trough of $144,000 in FY2020.
  • In the last 2 years, CRISPR Therapeutics AG's Receivables - Net had a median value of $112.5 million in 2023 and averaged $112.5 million.
  • In the last 5 years, CRISPR Therapeutics AG's Receivables - Net soared by 111.81% in 2021 and then slumped by 87.50% in 2024.
  • Yearly analysis of 4 years shows CRISPR Therapeutics AG's Receivables - Net stood at $144,000 in 2020, then spiked by 111.81% to $305,000 in 2021, then reached $200.0 million in 2023, then tumbled by 87.50% to $25.0 million in 2024.